10,800.00p-8.00 (-0.07%)05 Jul 2022, 07:15
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.
Jump to:

Astrazeneca PLC Fundamentals

Company NameAstrazeneca PLCLast Updated2022-07-05
IndustryDrug Manufacturers - GeneralSectorHealthcare
Shares in Issue1.549 bnMarket Cap£167.34 bn
PE Ratio1,666.67Dividend per Share$2.80
Dividend Yield1.95Dividend Cover0.03
EPS$0.08EPS Growth (%)0
PEG1.46DPS Growth (%)-0.0006
Debt Ratio0.3101Debt Equity Ratio0.7927
Asset Equity Ratio2.7579Cash Equity Ratio0.1602
Quick Ratio0.6379Current Ratio1.00
Price To Book Value5.5772ROCE0

Astrazeneca PLC Dividends

TypeEx-DatePay DateCurrencyNet DividendYear Total

Astrazeneca PLC Company Financials

Tangible Assets$10.17 bn$8.92 bn$8.34 bn
Intangible Assets$62.38 bn$32.79 bn$32.50 bn
Investments$1.24 bn$1.15 bn$1.46 bn
Total Fixed Assets$79.12 bn$47.19 bn$45.81 bn
Stocks$8.98 bn$4.02 bn$3.19 bn
Debtors$8.13 bn$5.29 bn$4.90 bn
Cash & Equivalents$6.40 bn$7.99 bn$6.22 bn
Other Assets$5.33 bn$4.33 bn$3.52 bn
Total Assets$105.36 bn$66.73 bn$61.38 bn
Creditors within 1 year$22.59 bn$20.31 bn$18.12 bn
Creditors after 1 year$43.48 bn$30.78 bn$28.66 bn
Other Liabilities000
Total Liabilities$66.08 bn$51.09 bn$46.78 bn
Net assets$39.29 bn$15.64 bn$14.60 bn
Called up share capital$387.00 m$328.00 m$328.00 m
Share Premium$35.28 bn$8.12 bn$8.09 bn
Profit / Loss-$265.00 m$3.92 bn$1.55 bn
Other Equity$39.27 bn$15.62 bn$13.13 bn
Preference & Minorities$19.00 m$16.00 m$1.47 bn
Total Capital Employed$39.29 bn$15.64 bn$14.60 bn
Debt Ratio$0.42$0.54$0.55
Assets / Equity2.75792.75792.7579
Cash / Equity0.16020.16020.1602
Cash Flow202120202019
Cash from operating activities$5.96 bn$4.80 bn$2.97 bn
Cashflow before financing$9.61 bn$2.60 bn$1.20 bn
Increase in Cash-$1.45 bn$2.31 bn$547.00 m
Turnover$37.42 bn$26.62 bn$24.38 bn
Cost of sales$12.44 bn$5.30 bn$4.92 bn
Gross Profit$24.98 bn$21.32 bn$19.46 bn
Operating Profit$1.06 bn$5.16 bn$2.92 bn
Pre-Tax profit-$265.00 m$3.92 bn$1.55 bn

Astrazeneca PLC Company Background

ActivitiesA merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Latest Interim Date29 Jul 2022
Latest Fiscal Year End Date10 Feb 2022

Astrazeneca PLC Directors

2016-12-01Mr. Jean-Philippe CourtoisNon-Executive Director
2010-11-16Ms. Michele J. HooperNon-Executive Director
1995-04-11Sir Peter Leahy Bonfield CBENon-Executive Director
2019-04-26Mr. Rudolph Harold Peter MarkhamNon-Executive Director
2020-03-06Ms. Sherilyn S. McCoyNon-Executive Director
2010-10-29Dr. Jane E Henney MDNon-Executive Director
2019-03-07Mr. David R BrennanExecutive Director,Chief Executive Officer
2009-10-30Mr. Bo AngelinNon-Executive Director
2000-12-22Ms. Erna MollerNon-Executive Director
2011-11-16Dr. Hakan L. MogrenNon-Executive Director,Deputy Chairman
2015-04-24Dr. John Silvester Varley Non-Executive Director
2011-08-09Mr. Jonathan Richard Symonds CBEExecutive Director,Chief Financial Officer
2020-03-06Mr. Leif JohanssonNon-Executive Director,Chairman
2012-06-01Mr. Louis SchweitzerNon-Executive Director,Chairman
2020-03-31Mr. Marc DunoyerExecutive Director,Chief Financial Officer
2019-03-07Mr. Marcus WallenbergNon-Executive Director
2020-02-19Mr. Michel DemareNon-Executive Director
2020-06-30Mr. Pascal SoriotExecutive Director,Chief Executive Officer
2020-12-16Mr. Philip A J BroadleyNon-Executive Director
2014-03-20Mr. Simon Jonathan LowthExecutive Director,Chief Financial Officer
2011-08-09Dr. John Simon Patterson, CBEExecutive Director
2015-04-24Professor Dame Nancy RothwellNon-Executive Director
2005-08-25Sir John BuchananNon-Executive Director
2020-03-06Mr. Graham Andrew ChipchaseNon-Executive Director,Senior independent Director
2020-03-06Professor Genevieve BergerNon-Executive Director
2017-11-13Dr. Bruce BurlingtonNon-Executive Director
2003-09-08Mr. Joe JimenezNon-Executive Director
2019-03-05Baroness Shriti Vadera Non-Executive Director
2017-04-27Ms. Ann CairnsNon-Executive Director
2020-03-06Ms. Deborah DiSanzoNon-Executive Director
2016-09-30Dr. Cornelia BargmannNon-Executive Director
2020-12-16Professor Nazneen RahmanNon-Executive Director
2020-03-20Professor Tony MokNon-Executive Director

Astrazeneca PLC Contact Details

Company NameAstraZeneca PLC
Address2 Kingdom Street, London, W2 6BD
Telephone+44 2076048000

Astrazeneca PLC Advisors

Phone+44 2073111000
Fax+44 2073113311
Remuneration ConsultantDeloitte LLP
Phone+44 2079363000
Fax+44 2075831198
Financial PR AdviserFinsbury
Phone+44 2072513801
Fax+44 2073744133
Phone+44 2075005500
RegistrarEquiniti Ltd.
Phone+44 1214157082
SolicitorFreshfields Bruckhaus Deringer
Phone+44 2079364000
Fax+44 2078327001
StockbrokerGoldman Sachs International
Phone+44 2077741000
StockbrokerMorgan Stanley & Co International PLC
Phone+44 2074258000
Fax+44 2074258990
Phone+1 212 758-9700
Fax+1 212 758-9819
AuditorKPMG Klynveld Peat Marwick Goerdeler SA